Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

thinkemotive

- PMLiVE

FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications

Cimerli belongs to the anti-VEGF therapy class of biologics that has helped retinal patients maintain or gain vision

- PMLiVE

Achieving communication excellence by targeting the right channel at the right time

By Danny Buckland It’s been a turbulent term for the pharmaceutical industry and the end of year reports make for patchy reading as the pandemic’s forced syllabus changes created a...

- PMLiVE

WHO, UNICEF and UNAIDS launch global alliance to end AIDS in children by 2030

Globally only 52% of children living with HIV are on life-saving treatment, compared to 76% of adults receiving antiretrovirals

- PMLiVE

Alzheimer’s Research UK calls for government action to address inequalities in dementia risk

The call comes as researchers presented findings demonstrating a link between socio-economic deprivation and higher dementia risk

- PMLiVE

Janssen’s Stelara approved by FDA for psoriatic arthritis in paediatric patients

Active psoriatic arthritis affects 5-8% of children and adolescents with chronic inflammatory arthritis

- PMLiVE

Arcutis receives FDA approval for steroid-free plaque psoriasis treatment

Zoryve is the first and only PDE4 inhibitor approved for plaque psoriasis

- PMLiVE

Boehringer Ingelheim and QUANTRO Therapeutics partner to develop drug candidates

The collaboration aims to offer a long-term strategy to provide breakthrough cancer treatments

- PMLiVE

Achieving communication excellence by targeting the right channel at the right time

By Danny Buckland

- PMLiVE

Innovation through collaboration – the importance of partnerships

By Mario Ippolito

- PMLiVE

‘Who moved my cheese?’

By Harriet Coady

- PMLiVE

Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection

Subcutaneously administering Tecentriq reduced the time needed for treatment compared to standard IV infusion

regeneron headquarters

Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV

The drug was taken off the US market in January due to it being ‘highly unlikely’ to be active against the Omicron variant

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links